Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Eli lilly and company symbols : Abcl save search
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
Published: 2021-12-03 (Crawled : 22:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: 3.41%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
covid therapy authorized antibody merge
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
Published: 2021-12-02 (Crawled : 15:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: -1.51%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
commercialization
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
Published: 2021-11-02 (Crawled : 23:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: -0.41%
H: 5.54%
C: 4.54%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
covid treatment
Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential
Published: 2021-10-26 (Crawled : 11:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: -1.7%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
RIGL | $1.15 -4.17% -3.45% 650K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
PRQR | $2.045 -7.05% -8.37% 320K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
DTIL | $13.06 -7.51% -8.45% 120K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
MRUS | $41.27 -1.39% -1.33% 270K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
financial results potential results growth
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
Published: 2021-09-21 (Crawled : 19:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: -0.58%
H: 3.16%
C: 2.68%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 2.04%
H: 0.72%
C: -0.81%
covid treatment
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: -0.11%
H: 5.8%
C: 5.38%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid fda merge authorized emergency use authorization
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: 1.14%
H: 0.0%
C: -1.56%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.75%
H: 5.97%
C: 4.59%
RIGL | $1.15 -4.17% -3.45% 650K
|
Health Technology
|
| O: 0.5%
H: 0.5%
C: -6.44%
DTIL | $13.06 -7.51% -8.45% 120K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: -1.21%
MRUS | $41.27 -1.39% -1.33% 270K
|
Health Technology
|
| O: 0.9%
H: 1.45%
C: 0.67%
financial results results liver
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: -0.65%
H: 10.38%
C: 8.4%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.87%
H: 1.36%
C: 0.36%
covid clinical trials antibody trial covid-19
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
Published: 2021-03-10 (Crawled : 17:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: 1.27%
H: 5.99%
C: 3.83%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.38%
H: 0.56%
C: -0.69%
covid phase 3 trial
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 07:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: 12.77%
H: 0.06%
C: -11.34%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda antibody merge authorized covid-19 emergency use authorization
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
Published: 2021-01-26 (Crawled : 13:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: 1.02%
H: 1.36%
C: -3.08%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.09%
H: 0.32%
C: 0.08%
covid antibody risk
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
Published: 2021-01-21 (Crawled : 23:00) - biospace.com/
ABCL | $4.18 -3.69% -3.58% 1.3M
|
|
| O: 1.66%
H: 5.08%
C: 3.88%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 1.21%
H: 0.5%
C: -0.66%
covid antibody risk
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
MDJH | $1.59 23.26% 19.88% 14K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.